Lab Innovations – Back for 2017!
News Jun 19, 2017
With the largest gathering of laboratory suppliers in the UK, this free-to-attend show has lots on offer for professionals across a wide range of sectors, from pharmaceuticals to food and drink.
Lab Innovations continues its strong links with the scientific community, with partners including GAMBICA, the Science Council, the Royal Society of Chemistry, Innovation DB and UKSPA for 2017. The packed schedule will cover the latest trends in laboratory science across three live theatres, including the all new Insights and Innovations theatre, which will feature debates about the latest advances in food and drink technology, life sciences and pharma. The Royal Society of Chemistry theatre will focus on the analysis of illicit substances – including cannabis and so-called ‘legal highs’ and counterfeit pharmaceuticals – as well as laboratory automation, in-process analysis and, new for this year, sessions from the Royal Society of Chemistry’s careers service.
Speaking about last year’s show, Leo Daly, Laboratory Supervisor at Lagan Cement, said: “It’s great to see so many exhibitors that are experts in the field, and to have them all in one place.” Tim Daniels, Marketing Manager at Autoscribe Informatics, agreed: “It’s a must attend event in the UK calendar.”
New exhibitors for 2017 will include Microlit, Thermo Fisher Scientific, VWR International, GS Biotech, Alphatech and LabVantage Solutions, and there will be over 150 exhibitors in total – such as Eppendorf, Shimadzu and Scientific Laboratory Supplies (SLS) – meaning the show is not to be missed. Come and hear inspiring speakers, find out about the latest products launches, network with fellow innovators, and get involved in interactive seminars and hands-on demonstrations.
360 New Disease Models Identified in Lab Mouse StudyNews
The research, which generated over 20 million pieces of data, has found 360 new disease models and provides 28,406 new descriptions of the genes’ effects on mouse biology and disease.READ MORE
LifeArc, Dstl and CDRD Collaborate to Identify Antibacterial Drug TargetsNews
Novel approach capitalises on commonality across pathogens.READ MORE
FDA to Fast Track Designation for Pfizer and Lilly's TanezumabNews
Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain.READ MORE